CenterBook Partners LP Sells 113,525 Shares of Royalty Pharma plc (NASDAQ:RPRX)

CenterBook Partners LP lessened its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 52.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,735 shares of the biopharmaceutical company's stock after selling 113,525 shares during the quarter. CenterBook Partners LP's holdings in Royalty Pharma were worth $2,672,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in RPRX. Brooklyn Investment Group boosted its position in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 876 shares during the period. Allworth Financial LP raised its holdings in shares of Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 877 shares during the last quarter. Riverview Trust Co boosted its position in shares of Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 1,186 shares during the period. Fifth Third Bancorp grew its holdings in Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 997 shares in the last quarter. Finally, Rakuten Securities Inc. increased its position in Royalty Pharma by 160.5% in the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 1,003 shares during the period. Institutional investors own 54.35% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have issued reports on RPRX. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Royalty Pharma has an average rating of "Buy" and an average target price of $42.50.

Royalty Pharma Stock Down 0.1 %

NASDAQ:RPRX traded down $0.04 during trading hours on Tuesday, hitting $32.25. 1,009,746 shares of the stock traded hands, compared to its average volume of 3,233,432. The firm has a 50 day moving average price of $32.52 and a 200 day moving average price of $29.17. The firm has a market cap of $18.59 billion, a price-to-earnings ratio of 22.24, a PEG ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities research analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.